Target validation and analysis in normal and diseased human brain tissue

Diereks2_wide.jpg

Diereks4wide.jpg

graphic_w.jpg

Jennifer SVZ amyg wide.jpg

Shelfw.jpg

THE NEUROVALIDA PLATFORM:

Assists companies and academia by providing services for CNS drug target validation and discovery utilizing adult human brain tissue microarrays, automated microscopy, and automated (high content) image analysis.

WE PROVIDE TWO LEVELS OF SERVICES:

  • Target validation and analysis where the client is sent high resolution digitized images of their target in human brain and a detailed report of our analysis.
  • Partnering with Biotech/Pharma/Academia to deliver a collaborative program of research around target discovery using a range of techniques on human brain tissues.

The principal goal for Neurovalida is to engage in contracts and collaborations with commercial entities to promote the development of medications for treating human brain disorders. Neurovalida will design and undertake research program utilizing human brain tissue for clients to achieve this goal at the highest ethical and scientific standards. Most importantly, this work recognizes the wishes of the generous human brain and brain tissue donors and their families to help develop treatments for these devastating brain disorders. 

NEUROVALIDA DEVELOPED BY:

Professor Mike Dragunow, Distinguished Professor Sir Richard Faull and Professor Maurice Curtis with a vision to promote the translation of CNS drug discovery to the clinic by improving drug target validation utilizing their expertise in human neuroanatomy and neurochemistry, human brain banking, human brain tissue microarray and high content screening.